Buy TB-500 Research Peptide

What is TB-500?

TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4, a natural protein that helps organize the cell’s internal scaffold (actin). It is studied in animal research for its effects on tissue repair and recovery.

• Based on the actin-binding region (LKKTET) of Thymosin Beta-4
• Studied in cell research for its effects on the actin scaffold and cell movement
• Studied in animal research for its effects on tissue repair and remodeling
• Investigated for its effects on blood-vessel growth and inflammation signaling

For research use only. Not approved for human therapeutic use.

TB-500 (CAS 885340-08-9), the synthetic form of Thymosin Beta-4 (Tβ4), is a 43-amino acid peptide with the molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S and a molecular weight of 4963.44 g/mol. Its full sequence (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser) features an N-terminal acetylation and contains the critical LKKTETQ actin-binding motif at positions 17-23. TB-500 belongs to a highly conserved family of 16 beta-thymosin isoforms and is one of the most abundant intracellular peptides in mammalian cells. Produced via solid-phase peptide synthesis, TB-500 functions as a G-actin sequestering protein.

TB-500 is central to preclinical cytoskeletal biology and tissue remodelling research. Its primary mechanism centres on the sequestration of monomeric globular actin (G-actin), regulating the equilibrium between G-actin monomers and polymerised filamentous actin (F-actin), a balance governing cell migration, morphogenesis, and cytoskeletal reorganisation. The conserved central LKKTET motif (positions 17-22) is essential for actin binding, but mutational mapping has shown that the isolated motif alone binds G-actin only weakly; high-affinity sequestration depends on additional contacts contributed by regions flanking the motif across the full-length peptide [1]. In vitro studies have examined TB-500 in endothelial cell, fibroblast, and keratinocyte preparations, documenting enhanced endothelial cell differentiation and capillary-like tube formation on reconstituted basement membrane [2], alongside directional cell migration and extracellular matrix (ECM) remodelling through matrix metalloproteinase (MMP) expression. In vivo rodent studies have investigated TB-500 in dermal wound, corneal injury, and cardiac ischaemia models, reporting accelerated full-thickness dermal wound closure accompanied by increased angiogenesis and collagen deposition [3], findings that span the neovascularisation, collagen-deposition, and inflammatory-to-proliferative phases of the tissue remodelling cascade.

TB-500 is manufactured in an ISO9001 certified laboratory to a guaranteed purity of ≥98%. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system to preserve compound integrity throughout the supply chain. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996 Jan 15;15(2):201-10.PubMed PMID: 86171952Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, Kleinman H. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-35.PubMed PMID: 145174303Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999 Sep;113(3):364-8.PubMed PMID: 10469335

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

TB-500 (CAS 885340-08-9), the synthetic form of Thymosin Beta-4 (Tβ4), is a 43-amino acid peptide with the molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S and a molecular weight of 4963.44 g/mol. Its full sequence (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser) features an N-terminal acetylation and contains the critical LKKTETQ actin-binding motif at positions 17-23. TB-500 belongs to a highly conserved family of 16 beta-thymosin isoforms and is one of the most abundant intracellular peptides in mammalian cells. Produced via solid-phase peptide synthesis, TB-500 functions as a G-actin sequestering protein.

TB-500 is central to preclinical cytoskeletal biology and tissue remodelling research. Its primary mechanism centres on the sequestration of monomeric globular actin (G-actin), regulating the equilibrium between G-actin monomers and polymerised filamentous actin (F-actin), a balance governing cell migration, morphogenesis, and cytoskeletal reorganisation. The conserved central LKKTET motif (positions 17-22) is essential for actin binding, but mutational mapping has shown that the isolated motif alone binds G-actin only weakly; high-affinity sequestration depends on additional contacts contributed by regions flanking the motif across the full-length peptide [1]. In vitro studies have examined TB-500 in endothelial cell, fibroblast, and keratinocyte preparations, documenting enhanced endothelial cell differentiation and capillary-like tube formation on reconstituted basement membrane [2], alongside directional cell migration and extracellular matrix (ECM) remodelling through matrix metalloproteinase (MMP) expression. In vivo rodent studies have investigated TB-500 in dermal wound, corneal injury, and cardiac ischaemia models, reporting accelerated full-thickness dermal wound closure accompanied by increased angiogenesis and collagen deposition [3], findings that span the neovascularisation, collagen-deposition, and inflammatory-to-proliferative phases of the tissue remodelling cascade.

TB-500 is manufactured in an ISO9001 certified laboratory to a guaranteed purity of ≥98%. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system to preserve compound integrity throughout the supply chain. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996 Jan 15;15(2):201-10.PubMed PMID: 86171952Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, Kleinman H. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-35.PubMed PMID: 145174303Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999 Sep;113(3):364-8.PubMed PMID: 10469335

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number885340-08-9Molecular Weight4963.4 g/molPurity≥99%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUTB500

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

TB-500 (CAS 885340-08-9), the synthetic form of Thymosin Beta-4 (Tβ4), is a 43-amino acid peptide with the molecular formula C₂₁₂H₃₅₀N₅₆O₇₈S and a molecular weight of 4963.44 g/mol. Its full sequence (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser) features an N-terminal acetylation and contains the critical LKKTETQ actin-binding motif at positions 17-23. TB-500 belongs to a highly conserved family of 16 beta-thymosin isoforms and is one of the most abundant intracellular peptides in mammalian cells. Produced via solid-phase peptide synthesis, TB-500 functions as a G-actin sequestering protein.

TB-500 is central to preclinical cytoskeletal biology and tissue remodelling research. Its primary mechanism centres on the sequestration of monomeric globular actin (G-actin), regulating the equilibrium between G-actin monomers and polymerised filamentous actin (F-actin), a balance governing cell migration, morphogenesis, and cytoskeletal reorganisation. The conserved central LKKTET motif (positions 17-22) is essential for actin binding, but mutational mapping has shown that the isolated motif alone binds G-actin only weakly; high-affinity sequestration depends on additional contacts contributed by regions flanking the motif across the full-length peptide [1]. In vitro studies have examined TB-500 in endothelial cell, fibroblast, and keratinocyte preparations, documenting enhanced endothelial cell differentiation and capillary-like tube formation on reconstituted basement membrane [2], alongside directional cell migration and extracellular matrix (ECM) remodelling through matrix metalloproteinase (MMP) expression. In vivo rodent studies have investigated TB-500 in dermal wound, corneal injury, and cardiac ischaemia models, reporting accelerated full-thickness dermal wound closure accompanied by increased angiogenesis and collagen deposition [3], findings that span the neovascularisation, collagen-deposition, and inflammatory-to-proliferative phases of the tissue remodelling cascade.

TB-500 is manufactured in an ISO9001 certified laboratory to a guaranteed purity of ≥98%. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system to preserve compound integrity throughout the supply chain. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996 Jan 15;15(2):201-10.PubMed PMID: 86171952Grant DS, Rose W, Yaen C, Goldstein A, Martinez J, Kleinman H. Thymosin beta4 enhances endothelial cell differentiation and angiogenesis. Angiogenesis. 1999;3(2):125-35.PubMed PMID: 145174303Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999 Sep;113(3):364-8.PubMed PMID: 10469335

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number885340-08-9Molecular Weight4963.4 g/molPurity≥99%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUTB500

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.